Leishmaniasis (Kala-Azar) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 100 pages | ID: L29E9579F3B3EN
VPAResearch

Abstracts

Leishmaniasis (Kala-Azar) Drug pipeline report- 2020 is an annual R&D review of Leishmaniasis (Kala-Azar) pipeline candidates. The report presents the current status of all major Leishmaniasis (Kala-Azar) therapeutic compounds. Detailed insights into Leishmaniasis (Kala-Azar) pipeline development, current status, companies, drug profiles and Leishmaniasis (Kala-Azar) preclinical and clinical trials are included.

2020 Leishmaniasis (Kala-Azar) Pipeline Market Insights
Leishmaniasis (Kala-Azar) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Leishmaniasis (Kala-Azar) therapies, pipeline by phase and others are included.

Leishmaniasis (Kala-Azar) pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Leishmaniasis (Kala-Azar) Therapeutic Drug candidates
Both active and inactive Leishmaniasis (Kala-Azar) pipeline drug candidates are included in the report

Leishmaniasis (Kala-Azar) Clinical Trials and preclinical Studies
Leishmaniasis (Kala-Azar) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Leishmaniasis (Kala-Azar) pipeline market developments
Leishmaniasis (Kala-Azar) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Leishmaniasis (Kala-Azar) pipeline companies in active development
The report analyzes Leishmaniasis (Kala-Azar) pipeline of the below companies-

Acea Biotech Inc, Anacor Pharmaceuticals , BioLingus AG, Cerenis Therapeutics Holding SA, Daiichi Sankyo Co Ltd, DetectoGen Inc, DNDi, Eurofins Advinus Ltd, Farmabrasilis, Fondation MEDINA, GlaxoSmithKline Plc, iCo Therapeutics Inc., Immune Modulation Inc, ManRos Therapeutics, Matinas BioPharma, Mindmed, Mologen AG, Novartis AG, Pfizer, Rakta Therapeutics Inc, Savant HWP Inc, Sequella Inc

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
22 Companies investing in Leishmaniasis (Kala-Azar) pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Leishmaniasis (Kala-Azar) pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included

Contents

1. LEISHMANIASIS (KALA-AZAR) PIPELINE MARKET INSIGHTS, 2020

1.1 Leishmaniasis (Kala-Azar) Disease Overview
1.2 Leishmaniasis (Kala-Azar) Drug Pipeline Snapshot, 2020
  1.2.1 Leishmaniasis (Kala-Azar) Pipeline Drugs by Phase
  1.2.2 Leishmaniasis (Kala-Azar) Pipeline Drugs by Company
  1.2.3 Leishmaniasis (Kala-Azar) Pipeline Drugs by Mechanism of Action
  1.2.4 Leishmaniasis (Kala-Azar) Pipeline Drugs by Route of Administration

2. LEISHMANIASIS (KALA-AZAR) COMPANY WISE PIPELINE DETAILS

Acea Biotech Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Anacor Pharmaceuticals Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
BioLingus AG Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Cerenis Therapeutics Holding SA Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Daiichi Sankyo Co Ltd Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
DetectoGen Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
DNDi Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Eurofins Advinus Ltd Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Farmabrasilis Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Fondation MEDINA Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
GlaxoSmithKline Plc Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
iCo Therapeutics Inc. Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Immune Modulation Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
ManRos Therapeutics Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Matinas BioPharma Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Mindmed Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Mologen AG Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Novartis AG Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Pfizer Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Rakta Therapeutics Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Savant HWP Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Sequella Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. LEISHMANIASIS (KALA-AZAR) DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. LEISHMANIASIS (KALA-AZAR) PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts